Dosing regimen for a selective s1p1 receptor agonist
US-2019151292-A1 · May 23, 2019 · US
Dosing regimen for a selective S1P1 receptor agonist
US12336980B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12336980-B2 |
| Application number | US-202218046492-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 13, 2022 |
| Priority date | Dec 11, 2014 |
| Publication date | Jun 24, 2025 |
| Grant date | Jun 24, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a human subject, diagnosed with multiple sclerosis, who has been orally administered once-daily titrating doses, successively over a period of two weeks, of a compound that is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz [Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof, which successive titrating doses are 2 mg on days 1 and 2; 3 mg of on days 3 and 4; 4 mg on days 5 and 6; 5 mg on day 7; 6 mg on day 8; 7 mg on day 9; 8 mg on day 10; and 9 mg on day 11, and 10 mg on days 12, 13, and 14, comprising: administering, starting on the day following the last titrating dose, 20 mg of said compound. 2. The method of claim 1 , wherein the multiple sclerosis is relapsing multiple sclerosis. 3. The method of claim 2 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis.
Assignees
Inventors
Classifications
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Drugs for dermatological disorders · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
for joint disorders, e.g. arthritis, arthrosis · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12336980B2 cover?
- The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.
- Who is the assignee on this patent?
- Vanda Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/426. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).